Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
04:25pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investo
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
08:05am, Monday, 29'th Dec 2025
PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re
INOVIO Reports Inducement Grant Under Inducement Plan
04:05pm, Friday, 19'th Dec 2025
PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
10:13am, Tuesday, 02'nd Dec 2025
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
INOVIO to Participate in December Investor Conferences
08:05am, Tuesday, 18'th Nov 2025
PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a
Inovio (INO) Upgraded to Buy: Here's Why
01:03pm, Friday, 14'th Nov 2025
Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress
09:53am, Wednesday, 12'th Nov 2025
Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash
INOVIO Announces Pricing of $25 Million Public Offering
08:40am, Tuesday, 11'th Nov 2025
PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pro
Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript
07:31pm, Monday, 10'th Nov 2025
Inovio Pharmaceuticals, Inc. ( INO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical
INOVIO Announces Proposed Public Offering
06:09pm, Monday, 10'th Nov 2025
PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Monday, 10'th Nov 2025
Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
08:05am, Monday, 03'rd Nov 2025
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designat
INOVIO Reports Inducement Grant Under Inducement Plan
04:53pm, Friday, 31'st Oct 2025
PLYMOUTH MEETING, Pa. , Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-r
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
08:05am, Monday, 27'th Oct 2025
PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
04:05pm, Thursday, 23'rd Oct 2025
PLYMOUTH MEETING, Pa. , Oct. 23, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a
